[[1, [[[74.0, 55.0, 90, 14], "antibiotics"], [[35.0, 103.0, 25, 10], "Article"], [[35.0, 116.0, 470, 20], "An Antisense yycF RNA Modulates Bio\ufb01lm Organization of"], [[36.0, 135.0, 497, 20], "Methicillin-Resistant Staphylococcus aureus and Pathogenicity"], [[35.0, 154.0, 252, 20], "in a Rat Model of Osteomyelitis"], [[35.0, 188.0, 234, 14], "Shizhou Wu 1, Yunjie Liu 2, Lei Lei 3,* and Hui Zhang 1,*"], [[36.0, 416.0, 85, 7], "Citation: Wu, S.; Liu, Y.; Lei, L.;"], [[36.0, 427.0, 91, 7], "Zhang, H. An Antisense yycF RNA"], [[35.0, 439.0, 90, 7], "Modulates Bio\ufb01lm Organization of"], [[35.0, 451.0, 97, 7], "Methicillin-Resistant Staphylococcus"], [[35.0, 463.0, 90, 7], "aureus and Pathogenicity in a Rat"], [[35.0, 475.0, 91, 7], "Model of Osteomyelitis. Antibiotics"], [[35.0, 487.0, 78, 7], "2021, 10, 603. https://doi.org/"], [[35.0, 499.0, 77, 7], "10.3390/antibiotics10050603"], [[35.0, 523.0, 84, 7], "Academic Editor: Jae-Seok Kim"], [[35.0, 547.0, 76, 7], "Received: 14 February 2021"], [[35.0, 559.0, 68, 7], "Accepted: 10 March 2021"], [[35.0, 571.0, 64, 7], "Published: 19 May 2021"], [[167.0, 219.0, 298, 13], "1 Department of Orthopedics, West China Hospital, Sichuan University, Chengdu 610041, China;"], [[180.0, 231.0, 88, 8], "wushizhou1990@wchscu.cn"], [[167.0, 241.0, 288, 13], "2 Department of Nutrition, Food Hygiene and Toxicology, West China School of Public Health,"], [[180.0, 253.0, 207, 8], "Sichuan University, Chengdu 610041, China; liuyunjie@scu.edu.cn"], [[167.0, 262.0, 291, 13], "3 Department of Preventive Dentistry, West China Hospital of Stomatology, Sichuan University,"], [[180.0, 274.0, 76, 8], "Chengdu 610041, China"], [[166.0, 285.0, 241, 8], "* Correspondence: leilei@scu.edu.cn (L.L.); zhanghui1437@wchscu.cn (H.Z.)"], [[166.0, 310.0, 358, 9], "Abstract: Staphylococcus aureus (S. aureus) is one of most common opportunistic pathogens and is"], [[167.0, 323.0, 341, 9], "attributed to several human infections. The increasing incidence of methicillin-resistant S. aureus"], [[166.0, 336.0, 338, 9], "(MRSA) is a serious clinical threat for osteomyelitis crisis. The YycFG two-component system of"], [[167.0, 349.0, 335, 9], "S. aureus regulates genes associated with bio\ufb01lm formation. To investigate the potential role of"], [[167.0, 362.0, 341, 9], "an antisense yycF RNA in the regulation of transcription levels of yycF and associated effects on"], [[167.0, 375.0, 342, 9], "bio\ufb01lm formation and pathogenicity, antisense yycF (ASyycF) RNA was detected by RT-PCR and"], [[167.0, 388.0, 343, 9], "5 RACE assays. ASyycF overexpression mutants were constructed, and the bio\ufb01lm biomass was"], [[167.0, 401.0, 350, 9], "determined by crystal violet microtiter assay and scanning electron microscopy (SEM). Quantitative"], [[167.0, 414.0, 359, 9], "RT-PCR and Western blotting analyses were used to detect whether ASyycF overexpression inhibited"], [[167.0, 427.0, 331, 9], "the transcription and translation of bio\ufb01lm-related genes. Then, a rat tibial infective model was"], [[167.0, 440.0, 331, 9], "used to evaluate the pathogenicity of ASyycF overexpression in vivo. ASyycF transcription led"], [[167.0, 453.0, 335, 9], "to reductions in YycF production and bio\ufb01lm formation. Overexpression of ASyycF inhibited the"], [[167.0, 466.0, 352, 9], "transcription and translation of bio\ufb01lm-related genes. The sensitivity to vancomycin was improved in"], [[166.0, 479.0, 356, 9], "ASyycF-overexpressing MRSA. Furthermore, ASyycF inhibited MRSA invasion in a rat tibial infection"], [[167.0, 492.0, 353, 9], "model. From this study, the expression of the YycF protein was found to be inversely correlated with"], [[167.0, 505.0, 337, 9], "different levels of ASyycF transcription. The bio\ufb01lm biomass and pathogenicity decreased in the"], [[166.0, 518.0, 358, 9], "ASyycF-overexpressing mutant. Thus, the current evidence may support ASyycF as a supplementary"], [[167.0, 531.0, 193, 9], "strategy for managing S. aureus and MRSA infections."], [[167.0, 556.0, 307, 9], "Keywords: antisense; bio\ufb01lm formation; Staphylococcus aureus; YycFG; osteomyelitis"], [[35.0, 596.0, 102, 7], "Publisher\u2019s Note: MDPI stays neutral"], [[35.0, 608.0, 96, 7], "with regard to jurisdictional claims in"], [[35.0, 620.0, 98, 7], "published maps and institutional af\ufb01l-"], [[36.0, 632.0, 19, 7], "iations."], [[36.0, 685.0, 93, 7], "Copyright: \u00a9 2021 by the authors."], [[36.0, 697.0, 95, 7], "Licensee MDPI, Basel, Switzerland."], [[35.0, 708.0, 96, 7], "This article is an open access article"], [[36.0, 720.0, 83, 7], "distributed under the terms and"], [[36.0, 732.0, 97, 7], "conditions of the Creative Commons"], [[35.0, 744.0, 93, 7], "Attribution (CC BY) license (https://"], [[36.0, 756.0, 90, 7], "creativecommons.org/licenses/by/"], [[36.0, 768.0, 14, 7], "4.0/)."], [[167.0, 605.0, 63, 10], "1. Introduction"], [[188.0, 620.0, 353, 10], "Staphylococcus aureus is one of most common opportunistic pathogens and is attributed"], [[167.0, 633.0, 351, 10], "to several human and animal infections [1,2]. As a main causative agent of osteomyelitis"], [[166.0, 646.0, 342, 10], "(OM) worldwide, S. aureus accounts for 50% to 80% of OM cases [3]. Antibiotics such"], [[167.0, 658.0, 346, 10], "as penicillin, methicillin, and glycopeptides have been used to \ufb01ght S. aureus infections"], [[167.0, 671.0, 354, 10], "for several decades. However, most antibiotics used to treat S. aureus infections not only"], [[167.0, 683.0, 350, 10], "have several side effects but also induce S. aureus to gain drug resistance against most"], [[167.0, 696.0, 344, 10], "antibiotics [4]. Although there is a debate on whether the abuse of antibiotics catalyzes"], [[167.0, 708.0, 364, 10], "the emergence of methicillin resistance in S. aureus (MRSA), the number of clinical isolates"], [[166.0, 721.0, 351, 10], "with MRSA is increasing, constituting a serious problem [5]. There is a robust demand to"], [[167.0, 734.0, 345, 10], "develop highly effective antibacterial agents to defeat this threatening resistance crisis."], [[188.0, 746.0, 337, 10], "S. aureus acts as a bio\ufb01lm producer and is an essential factor in its pathogenicity [6]."], [[167.0, 759.0, 344, 10], "Bio\ufb01lm formation is a physical barrier that allows bacteria to evade the immune system"], [[35.0, 815.0, 214, 8], "Antibiotics 2021, 10, 603. https://doi.org/10.3390/antibiotics10050603"], [[399.0, 815.0, 124, 8], "https://www.mdpi.com/journal/antibiotics"]], [841, 595]], [10, [[[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[532.0, 54.0, 25, 8], "10 of 12"], [[167.0, 98.0, 354, 10], "diameter according to our previous instructions [10]. Subsequently, protein samples were"], [[167.0, 109.0, 344, 15], "collected by centrifugation (12,000\u00d7 g for 2 min at 4 \u25e6C) for Western blotting. A puri\ufb01ed"], [[166.0, 123.0, 345, 10], "YycF-speci\ufb01c rabbit polyclonal antibody (HuaAn Biotechnology, Hangzhou, China) was"], [[167.0, 134.0, 342, 14], "used as a probe following our previous study [10]. A BioRad ChemiDocTM MP Imaging"], [[167.0, 148.0, 295, 10], "System (Hercules, CA, USA) was used to detect the density of blot bands."], [[167.0, 171.0, 167, 10], "4.8. Osteomyelitis in an In Vivo Rat Model"], [[188.0, 186.0, 328, 10], "Animal experiments were approved by our institutional Animal Welfare Committee."], [[167.0, 199.0, 359, 10], "Female Sprague\u2013Dawley rats (260\u2013280 g) were used for experiments conducted as previ-"], [[167.0, 211.0, 344, 10], "ously described [27]. Brie\ufb02y, the hind leg anteromedial tibia cortex was exposed, and a"], [[167.0, 224.0, 358, 10], "0.1-cm-diameter hole was made deep in the medullary cavity. Two groups, namely, MRSA"], [[167.0, 236.0, 352, 10], "and ASyycF MRSA, were evaluated. After four weeks, the rats were sacri\ufb01ced, and bone"], [[167.0, 249.0, 194, 10], "specimens were obtained for further evaluations."], [[167.0, 271.0, 310, 10], "4.9. Histological Evaluation and Fluorescent In Situ Hybridization Examination"], [[188.0, 287.0, 320, 10], "For histological evaluation, samples were prepared as previously described [27]."], [[167.0, 300.0, 348, 10], "Brie\ufb02y, tibia samples were prepared with 10% neutral buffered formalin and 10% EDTA."], [[167.0, 312.0, 330, 10], "Five-micrometer sections were processed with HE staining for observation. A FAM-"], [[167.0, 325.0, 346, 10], "labeled PNA probe (5 -FAM-GAAGCAAGCTTCTCGTCCG-FAM-3 ) targeting S. aureus"], [[166.0, 337.0, 341, 10], "16S rRNA (Servicebio, Wuhan, China) was applied for \ufb02uorescent in situ hybridization"], [[167.0, 350.0, 69, 10], "examination [15]."], [[167.0, 372.0, 97, 10], "4.10. Statistical Analysis"], [[188.0, 388.0, 310, 10], "One-way ANOVA and pairwise multiple comparisons of Tukey\u2019s test were con-"], [[167.0, 400.0, 354, 10], "ducted using SPSS software 18.0 (SPSS, Inc., Chicago, IL, USA). Data are presented as"], [[167.0, 413.0, 322, 12], "the mean \u00b1 SD; p < 0.05 was considered a statistically signi\ufb01cant difference [15]."], [[167.0, 435.0, 64, 10], "5. Conclusions"], [[188.0, 451.0, 329, 10], "In the current study, an antisense RNA base paired with yycF mRNA was identi\ufb01ed"], [[167.0, 463.0, 362, 10], "that contributes to the regulation of essential YycFG TCSs. The reactivity of antisense yycF"], [[167.0, 476.0, 353, 10], "RNA is inversely associated with both the transcription of yycF mRNA and the production"], [[167.0, 488.0, 354, 10], "of the YycF protein. Consequently, overexpression of ASyycF signi\ufb01cantly downregulated"], [[167.0, 501.0, 344, 10], "bio\ufb01lm formation and pathogenicity in S. aureus while elevating its antibiotic sensitivity,"], [[166.0, 513.0, 366, 10], "which was mainly dominated by the YycFG pathway via ica and sarA. Furthermore, ASyycF,"], [[167.0, 526.0, 368, 10], "as a posttranscriptional modulator of yycF, reveals potential as a novel strategy for S. aureus"], [[167.0, 539.0, 206, 10], "infections, such as in the treatment of osteomyelitis."], [[166.0, 563.0, 343, 9], "Author Contributions: Conceptualization, L.L.; data curation, S.W. and Y.L.; funding acquisition,"], [[167.0, 575.0, 340, 9], "H.Z.; investigation, S.W. and L.L.; methodology, S.W., L.L., and H.Z.; supervision, H.Z.; writing\u2014"], [[167.0, 587.0, 345, 9], "original draft, S.W., Y.L., L.L., and H.Z.; writing\u2014review and editing, S.W., Y.L., L.L., and H.Z., L.L."], [[167.0, 598.0, 340, 9], "and H.Z. contributed equally to this paper (co-corresponding authors). All authors have read and"], [[167.0, 610.0, 177, 9], "agreed to the published version of the manuscript."], [[167.0, 628.0, 351, 9], "Funding: This work was supported in part by the Sichuan Provincial Natural Science Foundation of"], [[167.0, 639.0, 369, 9], "China (Grant No. 2019YFS0270; 2021YJ0455) and Post-Doctor Research Project, West China Hospital,"], [[167.0, 651.0, 166, 9], "Sichuan University (Grant No. 2020HXBH134)."], [[167.0, 669.0, 351, 9], "Institutional Review Board Statement: The Animal Experiments Committee at Sichuan University"], [[167.0, 680.0, 229, 9], "approved all experiments in this study (Approval No. 2020042A)."], [[167.0, 698.0, 168, 9], "Informed Consent Statement: Not Applicable."], [[167.0, 716.0, 160, 9], "Data Availability Statement: Not Applicable."], [[167.0, 734.0, 229, 9], "Con\ufb02icts of Interest: The authors declare no con\ufb02ict of interest."]], [841, 595]], [11, [[[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[532.0, 54.0, 25, 8], "11 of 12"], [[36.0, 98.0, 49, 10], "References"], [[36.0, 113.0, 442, 9], "1. Wu, S.; Liu, Y.; Zhang, H.; Lei, L. A new transformation method with nanographene oxides of antisense carrying yycG RNA"], [[57.0, 125.0, 450, 9], "improved antibacterial properties on methicillin-resistant Staphylococcus aureus bio\ufb01lm. J. Vet. Med. Sci. 2019, 81, 1540\u20131546."], [[57.0, 136.0, 38, 9], "[CrossRef]"], [[36.0, 148.0, 436, 9], "2. Algammal, A.M.; Hetta, H.F.; Elkelish, A.; Alkhalifah, D.H.H.; Hozzein, W.N.; Batiha, G.E.-S.; El Nahhas, N.; Mabrok, M.A."], [[57.0, 159.0, 460, 9], "Methicillin-Resistant Staphylococcus aureus (MRSA): One Health Perspective Approach to the Bacterium Epidemiology, Virulence"], [[57.0, 171.0, 375, 9], "Factors, Antibiotic-Resistance, and Zoonotic Impact. Infect. Drug Resist. 2020, 13, 3255\u20133265. [CrossRef]"], [[36.0, 182.0, 462, 9], "3. Yu, K.; Song, L.; Kang, H.P.; Kwon, H.-K.; Back, J.; Lee, F.Y. Recalcitrant methicillin-resistant Staphylococcus aureus infection of"], [[57.0, 194.0, 353, 9], "bone cells: Intracellular penetration and control strategies. Bone Jt. Res. 2020, 9, 49\u201359. [CrossRef]"], [[36.0, 205.0, 471, 9], "4. Jayakumar, J.; Kumar, V.A.; Biswas, L.; Biswas, R. Therapeutic applications of lysostaphin against Staphylococcus aureus. J. Appl."], [[57.0, 217.0, 96, 9], "Microbiol. 2020. [CrossRef]"], [[36.0, 228.0, 425, 9], "5. Gajd\u00e1cs, M. The Continuing Threat of Methicillin-Resistant Staphylococcus aureus. Antibiotics 2019, 8, 52. [CrossRef]"], [[36.0, 240.0, 465, 9], "6. Wu, S.; Huang, F.; Zhang, H.; Lei, L. Staphylococcus aureus bio\ufb01lm organization modulated by YycFG two-component regulatory"], [[57.0, 251.0, 234, 9], "pathway. J. Orthop. Surg. Res. 2019, 14, 10. [CrossRef] [PubMed]"], [[36.0, 263.0, 476, 9], "7. Mosselhy, D.A.; Assad, M.; Sironen, T.; Elbahri, M. Nanotheranostics: A Possible Solution for Drug-Resistant Staphylococcus aureus"], [[57.0, 274.0, 208, 9], "and their Bio\ufb01lms? Nanomaterials 2021, 11, 82. [CrossRef]"], [[36.0, 286.0, 452, 9], "8. Da Costa, D.; Exbrayat-H\u00e9ritier, C.; Rambaud, B.; Megy, S.; Terreux, R.; Verrier, B.; Primard, C. Surface charge modulation of"], [[57.0, 297.0, 447, 9], "rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus bio\ufb01lms. J. Nanobiotechnol. 2021,"], [[57.0, 309.0, 64, 9], "19, 12. [CrossRef]"], [[36.0, 320.0, 457, 9], "9. Nguyen, H.T.T.; Nguyen, T.H.; Otto, M. The staphylococcal exopolysaccharide PIA\u2014Biosynthesis and role in bio\ufb01lm for-mation,"], [[57.0, 332.0, 359, 9], "colonization, and infection. Comput. Struct. Biotechnol. J. 2020, 18, 3324\u20133334. [CrossRef] [PubMed]"], [[36.0, 343.0, 475, 9], "10. Wu, S.; Liu, Y.; Lei, L.; Zhang, H. Antisense yycG Regulation of Antibiotic Sensitivity of Methicillin-Resistant Staphylococcus aureus"], [[57.0, 355.0, 282, 9], "in Chronic Osteomyelitis. Surg. Infect. (Larchmt) 2019, 20, 472\u2013479. [CrossRef]"], [[36.0, 366.0, 479, 9], "11. Tierney, A.R.; Rather, P.N. Roles of two-component regulatory systems in antibiotic resistance. Future Microbiol. 2019, 14, 533\u2013552."], [[57.0, 378.0, 74, 9], "[CrossRef] [PubMed]"], [[36.0, 390.0, 471, 9], "12. Wu, S.; Lin, K.; Liu, Y.; Zhang, H.; Lei, L. Two-component signaling pathways modulate drug resistance of Staphylococcus aureus"], [[57.0, 401.0, 129, 9], "(Review). Biomed. Rep. 2020, 13, 5."], [[36.0, 413.0, 469, 9], "13. Rapun-Araiz, B.; Haag, A.F.; De Cesare, V.; Gil, C.; Dorado-Morales, P.; Penades, J.R.; Lasa, I. Systematic Reconstruction of the"], [[57.0, 424.0, 430, 9], "Complete Two-Component Sensorial Network in Staphylococcus aureus. mSystems 2020, 5, e00511\u2013e00520. [CrossRef]"], [[36.0, 435.0, 474, 9], "14. Villanueva, M.; Garc\u00eda, B.; Valle, J.; Rap\u00fan, B.; de Los Mozos, I.R.; Solano, C.; Mart\u00ed, M.; Penad\u00e9s, J.R.; Toledo-Arana, A.; Lasa, I."], [[57.0, 447.0, 309, 9], "Sensory deprivation in Staphylococcus aureus. Nat. Commun. 2018, 9, 523. [CrossRef]"], [[36.0, 459.0, 435, 9], "15. Wu, S.; Liu, Y.; Lei, L.; Zhang, H. Endogenous antisense walR RNA modulates bio\ufb01lm organization and pathogenicity of"], [[57.0, 470.0, 185, 9], "Enterococcus faecalis. Exp. Ther. Med 2020, 21, 69."], [[36.0, 482.0, 459, 9], "16. Lei, L.; Stipp, R.N.; Chen, T.; Wu, S.Z.; Hu, T.; Duncan, M.J. Activity of Streptococcus mutans VicR Is Modulated by An-tisense"], [[57.0, 493.0, 224, 9], "RNA. J. Dent. Res. 2018, 97, 1477\u20131484. [CrossRef] [PubMed]"], [[36.0, 504.0, 465, 9], "17. Lakhundi, S.; Zhang, K. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epide-miology."], [[57.0, 516.0, 245, 9], "Clin. Microbiol. Rev. 2018, 31, e00018\u2013e00020. [CrossRef] [PubMed]"], [[36.0, 527.0, 469, 9], "18. Gould, I. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int. J. Antimicrob. Agents"], [[57.0, 539.0, 109, 9], "2006, 28, 379\u2013384. [CrossRef]"], [[36.0, 551.0, 475, 9], "19. Suresh, M.K.; Biswas, R.; Biswas, L. An update on recent developments in the prevention and treatment of Staphylococcus aureus"], [[57.0, 562.0, 210, 9], "bio\ufb01lms. Int. J. Med. Microbiol. 2019, 309, 1\u201312. [CrossRef]"], [[36.0, 574.0, 469, 9], "20. Wu, S.; Liu, Y.; Lei, L.; Zhang, H. Nanographene oxides carrying antisense walR RNA regulates the Enterococcus faecalis bio\ufb01lm"], [[57.0, 585.0, 353, 9], "formation and its susceptibility to chlorhexidine. Lett. Appl. Microbiol. 2020, 71, 451\u2013458. [CrossRef]"], [[36.0, 597.0, 485, 9], "21. Uru\u00e9n, C.; Chopo-Escuin, G.; Tommassen, J.; Mainar-Jaime, R.C.; Arenas, J. Bio\ufb01lms as Promoters of Bacterial Antibiotic Resistance"], [[57.0, 608.0, 175, 9], "and Tolerance. Antibiotics 2020, 10, 3. [CrossRef]"], [[36.0, 620.0, 449, 9], "22. Ceri, H.; Olson, M.E.; Stremick, C.; Read, R.R.; Morck, D.; Buret, A. The Calgary Bio\ufb01lm Device: New Technology for Rapid"], [[57.0, 631.0, 442, 9], "Determination of Antibiotic Susceptibilities of Bacterial Bio\ufb01lms. J. Clin. Microbiol. 1999, 37, 1771\u20131776. [CrossRef] [PubMed]"], [[35.0, 643.0, 476, 9], "23. Rodvold, K.A.; McConeghy, K.W. Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future. Clin. Infect. Dis."], [[57.0, 654.0, 111, 9], "2013, 58, S20\u2013S27. [CrossRef]"], [[36.0, 666.0, 462, 9], "24. Figueiredo, A.M.S.; Ferreira, F.A.; Beltrame, C.O.; C\u00f4rtes, M.F. The role of bio\ufb01lms in persistent infections and factors in-volved"], [[57.0, 677.0, 450, 9], "in ica-independent bio\ufb01lm development and gene regulation in Staphylococcus aureus. Crit. Rev. Microbiol. 2017, 43, 602\u2013620."], [[57.0, 689.0, 38, 9], "[CrossRef]"], [[36.0, 700.0, 464, 9], "25. Jamal, M.; Ahmad, W.; Andleeb, S.; Jalil, F.; Imran, M.; Nawaz, M.A.; Hussain, T.; Ali, M.; Ra\ufb01q, M.; Kamil, M.A. Bacterial bio\ufb01lm"], [[57.0, 712.0, 301, 9], "and associated infections. J. Chin. Med. Assoc. 2018, 81, 7\u201311. [CrossRef] [PubMed]"], [[35.0, 723.0, 447, 9], "26. Tande, A.J.; Osmon, D.R.; Greenwood-Quaintance, K.E.; Mabry, T.M.; Hanssen, A.D.; Patel, R. Clinical Characteristics and"], [[57.0, 735.0, 459, 9], "Outcomes of Prosthetic Joint Infection Caused by Small Colony Variant Staphylococci. mBio 2014, 5, e01910\u2013e01914. [CrossRef]"], [[35.0, 746.0, 476, 9], "27. Wu, S.; Liu, Y.; Lei, L.; Zhang, H. Virulence of methicillin-resistant Staphylococcus aureus modulated by the YycFG two-component"], [[57.0, 758.0, 315, 9], "pathway in a rat model of osteomyelitis. J. Orthop. Surg. Res. 2019, 14, 1\u201310. [CrossRef]"]], [841, 595]], [12, [[[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[532.0, 54.0, 25, 8], "12 of 12"], [[36.0, 99.0, 471, 9], "28. Wu, S.; Liu, Y.; Zhang, H.; Lei, L. The Pathogenicity and Transcriptome Analysis of Methicillin-Resistant Staphylococcus aureus in"], [[57.0, 110.0, 410, 9], "Response to Water Extract of Galla chinensis. Evid.-Based Complement. Altern. Med. 2019, 2019, 1\u201310. [CrossRef]"], [[35.0, 122.0, 461, 9], "29. Aktas, G. Ef\ufb01cacy of vancomycin in combination with various antimicrobial agents against clinical methicillin resistant Staphylo-"], [[57.0, 133.0, 253, 9], "coccus aureus strains. Pak. J. Med. Sci. 2020, 37, 151\u2013156. [CrossRef]"]], [841, 595]], [2, [[[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[536.0, 54.0, 21, 8], "2 of 12"], [[167.0, 96.0, 335, 10], "and enhances resistance to conventional antibiotics up to 1000-fold, which results in"], [[167.0, 109.0, 353, 10], "therapeutic failures. Drug resistance in bio\ufb01lms is mostly associated with the slow growth"], [[167.0, 122.0, 332, 10], "of bacteria and the dif\ufb01cult diffusion of antibacterial agents. Therefore, tolerance will"], [[167.0, 134.0, 335, 10], "be lost in planktonic form with the dispersion of bio\ufb01lms [7,8]. In bio\ufb01lm organization,"], [[166.0, 147.0, 355, 10], "polysaccharide intercellular adhesin (PIA) is the major extracellular polysaccharide (EPS)"], [[167.0, 159.0, 356, 10], "encoded by the ica gene that participates in pathogenesis, including bio\ufb01lm formation and"], [[167.0, 172.0, 93, 10], "immune evasion [9,10]."], [[188.0, 184.0, 323, 10], "Two-component regulatory systems (TCSs) exist ubiquitously in bacteria to adapt"], [[167.0, 197.0, 339, 10], "to stimuli and nutrition alterations from the external environment [11,12]. Typically, the"], [[166.0, 209.0, 355, 10], "TCS contains a histidine kinase (HK), which can autophosphorylate a conserved histidine"], [[167.0, 222.0, 347, 10], "residue in response to extracellular stimulus, and a response regulator (RR), which can"], [[167.0, 234.0, 343, 10], "transfer the phosphoryl group from HK [13]. Among 16 TCSs in S. aureus, only YycFG"], [[167.0, 247.0, 349, 10], "is essential for bacterial viability [14]. In our previous study, YycFG modulated ica genes"], [[167.0, 260.0, 350, 10], "that are involved in bio\ufb01lm development, and the expression of YycFG was signi\ufb01cant in"], [[167.0, 272.0, 346, 10], "MRSA strains [6]. From this point of view, YycFG has the potential to be a target for the"], [[167.0, 285.0, 119, 10], "treatment of MRSA infections."], [[188.0, 297.0, 331, 10], "Antisense RNA (AS RNA), a kind of noncoding RNA, can be bound by base-pairing"], [[167.0, 310.0, 337, 10], "to the target messenger RNA (mRNA). Their interactions result in the formation of an"], [[167.0, 322.0, 352, 10], "RNA duplex structure, which generally regulates gene expression and downstream func-"], [[167.0, 335.0, 367, 10], "tions [15,16]. In our previous studies, endogenous vicR antisense and walR antisense RNAs"], [[166.0, 347.0, 367, 10], "were identi\ufb01ed in Streptococcus mutans and Enterococcus faecalis, respectively [15,16]. Ac-"], [[167.0, 360.0, 344, 10], "cording to these investigations, the effect of antisense RNA has an inverse association"], [[166.0, 373.0, 350, 10], "with TCS expression and bio\ufb01lm formation [10]. In the present study, whether a potential"], [[167.0, 385.0, 360, 10], "antisense yycF RNA exists was hypothesized, and whether the potential ASyycF is speci\ufb01-"], [[167.0, 398.0, 350, 10], "cally associated with the regulation of YycF function in S. aureus and MRSA strains was"], [[167.0, 410.0, 70, 10], "also investigated."], [[167.0, 433.0, 43, 10], "2. Results"], [[167.0, 446.0, 262, 10], "2.1. ASyycF Modulated Bacterial Growth and Bio\ufb01lm Organization"], [[188.0, 462.0, 333, 10], "We investigated whether a potential antisense RNA was speci\ufb01cally associated with"], [[167.0, 474.0, 342, 10], "yycF using \ufb01rst-strand cDNA synthesis. Total RNA was prepared from the ATCC29213"], [[167.0, 487.0, 350, 10], "strain grown as planktonic or bio\ufb01lm cultures in TSB medium. These RNA samples were"], [[167.0, 499.0, 351, 10], "used as templates for \ufb01rst-strand DNA synthesis using yycF antisense-speci\ufb01c (SAPCR)"], [[167.0, 512.0, 368, 10], "and sense-speci\ufb01c primers (SAAS, Table 1). ASyycF transcript of the predicted size (approx-"], [[167.0, 524.0, 355, 10], "imately 400 bases) was detected, as shown in Figure 1A. We used 5 RACE for additional"], [[167.0, 537.0, 365, 10], "con\ufb01rmation of ASyycF, and the primers used in the PCRs are listed in Table 1. The position"], [[167.0, 549.0, 356, 10], "of primers used for 5 RACE assays and gel electrophoresis of the 5 RACE PCR amplicon"], [[167.0, 562.0, 350, 10], "are indicated in Figure 1B. The sequence predicts that the 5 terminus of AS yycF begins"], [[166.0, 574.0, 363, 10], "within the yycF coding sequences. The growth curves of ATCC29213, ASyycF ATCC29213,"], [[167.0, 587.0, 355, 10], "MRSA, and ASyycF MRSA strains were compared in three independent experiments. For"], [[167.0, 600.0, 348, 10], "the growth curve, ASyycF-overexpressing MRSA and ATCC29213 strains were delayed"], [[167.0, 612.0, 344, 10], "from entering into log phase by three hours compared with the MRSA and ATCC29213"], [[167.0, 625.0, 369, 10], "strains (Figure 2A). By quantitative crystal violet microtiter assays, the biomasses of ASyycF-"], [[167.0, 637.0, 349, 10], "overexpressing MRSA and ATCC29213 bio\ufb01lms showed nearly twofold decreases com-"], [[166.0, 650.0, 351, 10], "pared with MRSA and ATCC29213 bio\ufb01lms (Figure 2B). SEM observations revealed that"], [[167.0, 662.0, 342, 10], "MRSA and ATCC29213 strains highly accumulated extracellular matrix compared with"], [[166.0, 675.0, 271, 10], "ASyycF-overexpressing MRSA and ATCC29213 strains (Figure 2C)."]], [841, 595]], [3, [[[9.0, 45.0, 129, 9], "Antibiotics 2021, 10, x FOR PEER REVIEW"], [[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[510.0, 45.0, 20, 9], "3 of 12"], [[536.0, 54.0, 21, 8], "3 of 12"], [[140.0, 86.0, 174, 13], "Table 1. Sequences of primers in this study."], [[56.0, 102.0, 34, 11], "Primers"], [[54.0, 114.0, 70, 17], "RT-qPCRPrimers"], [[64.0, 131.0, 55, 11], "icaA RT-qPCR"], [[63.0, 151.0, 38, 15], "yycF icaA"], [[63.0, 173.0, 40, 15], "yycG yycF"], [[64.0, 195.0, 40, 15], "sarA yycG"], [[100.0, 217.0, 16, 9], "sarA"], [[63.0, 223.0, 19, 11], "icaD"], [[100.0, 239.0, 16, 9], "icaD"], [[53.0, 246.0, 40, 11], "16S rRNA"], [[36.0, 261.0, 108, 15], "AS yycF dete1c6tiSornRNA"], [[31.0, 276.0, 142, 17], "First strandAsSyynythcFesdisetection"], [[57.0, 287.0, 105, 17], "SAFPirCstRstrand synthesis"], [[36.0, 299.0, 101, 17], "AS yycF detecStiAonPCR"], [[60.0, 310.0, 90, 17], "SAAASS yycF detection"], [[56.0, 322.0, 58, 17], "5\u2032RACE SAAS"], [[92.0, 337.0, 29, 9], "5 RACE"], [[40.0, 350.0, 66, 11], "5\u2032RACE adapter"], [[76.0, 364.0, 58, 9], "5 RACE adapter"], [[193.0, 98.0, 290, 15], "SequTeanbclee 51\u2032.-S3e\u2032q(uFeonrcwesarodf /pRriemveerrssei)n this study."], [[229.0, 119.0, 126, 9], "Sequence 5 -3 (Forward/Reverse)"], [[188.0, 126.0, 159, 11], "5\u2032-GATTATGTAATGTGCTTGGA-3\u2032/"], [[190.0, 137.0, 155, 11], "5\u2032-ACTACTGCTGCGTTAATAAT-3\u2032"], [[191.0, 146.0, 280, 15], "5\u2032-TGGC5G-GAAATATAGTAGATGAAACTGATTGCCAT-3T\u2032G/ GA-3 /"], [[195.0, 157.0, 264, 15], "5\u2032-AAC5CC-AGCTTTAACCTAGACTAGTCCGCTTTGA-3A\u2032TAAT-3"], [[185.0, 168.0, 285, 15], "5\u2032-CGGGG5 C-TGGTGTCCGAAAAAAAGGAAACGTATCTA-3T\u2032C/ A-3 /"], [[184.0, 179.0, 281, 15], "5\u2032-TCTGAA5 C-ACATCTCTCGGATATCAACCAAACAGTCT-C3T\u2032 G-3"], [[187.0, 190.0, 289, 15], "5\u2032-AGAT5G-CGGCGCGCGTTCCGTTTTCCAAAAAAATGGA-3C\u2032/TTT-3 /"], [[189.0, 200.0, 412, 17], "5\u2032-CCGC55A--TAACGTTAAGATAGTATGCCCCTCTTCTGTTTTGCGATAATCCCGAA-CA3AA\u2032 CTGG-T3-3/"], [[184.0, 218.0, 290, 17], "5\u2032-ATGGT5C-ACCAGGCCACACTAAGAATCTCATGTAGGTG-3A\u2032/ CG-3"], [[179.0, 229.0, 310, 17], "5\u2032-CGTGT5T-TATTGCGATACCAAATGTCTACCATAGGCAACAAG-3A\u2032 G-3 /"], [[186.0, 241.0, 300, 17], "5\u2032-GTA5G-GCTGGTGGCTTATATGCACGATCTAATTTCTACA-3T\u2032G/ CAA-3"], [[193.0, 252.0, 278, 11], "5\u2032-CGC5A-CGATATCGAGTGGCGGCTACAAGACCGAT-T3A\u2032 TCC-3 /"], [[228.0, 266.0, 117, 9], "5 -CGCACATCAGCGTCAACA-3"], [[159.0, 281.0, 222, 11], "5\u2032-CGTATTATTAGATATCATGTTACCTGGTCG-3\u2032"], [[197.0, 298.0, 173, 9], "5 -CGTATTATTAGATATCATGTTACCTGGTCG-3"], [[164.0, 304.0, 207, 11], "5\u2032-GTTCACGTGTCATTACTTGTCCCATATG-3\u2032"], [[202.0, 320.0, 166, 9], "5 -GTTCACGTGTCATTACTTGTCCCATATG-3"], [[189.0, 345.0, 153, 11], "5\u2032-GCUGAUGGCGAUGAAUGAAC"], [[171.0, 356.0, 315, 11], "ACUGCGUU5U-GGCCUUGGAGUCGUGUCUGGAAUUGGAAAAUAG-A3A\u2032 C"], [[206.0, 370.0, 152, 9], "ACUGCGUUUGCUGGCUUUGAUGAAA-3"], [[22.0, 385.0, 102, 11], "5\u2032 RACE outer primer (c)"], [[174.0, 385.0, 187, 11], "5\u2032-GCTGATGGCGATGAATGAACACTG-3\u2032"], [[59.0, 397.0, 424, 15], "5 RACE outer primer (c) 5\u2032-CGCG5G-AGTCCTCGGAATGAGCCAGCATTGGCAGATTTGTAGACCTAGCTG-3"], [[22.0, 408.0, 103, 11], "5\u2032 RACE inner primer (d)"], [[58.0, 419.0, 86, 9], "5 RACE inner primer (d)"], [[209.0, 413.0, 227, 15], "5 -CGGCCGTGTATTGCACTGGA-A3\u2032CACTGCGTTTGCTG"], [[13.0, 425.0, 121, 11], "Gene specific outer primer (a)"], [[162.0, 424.0, 270, 15], "5\u2032-GGCGAAGATATTGAGACTTTTATAGCAATCGA-3TCGTG-3\u2032"], [[13.0, 435.0, 599, 15], "Gene speGciefinceisnpneecri\ufb01pcriomuetrer(bp)rimer (a5)\u2032-CATAT5G-GGGGCAGCAAAAGGATTAAATTTGGAACAATTCAGATCGAACAACT-C3G\u2032 TG-3"], [[49.0, 446.0, 105, 9], "Gene speci\ufb01c inner primer (b)"], [[197.0, 446.0, 169, 9], "5 -CATATGGGACAAGTAATGACACGTGAAC-3"], [[442.0, 102.0, 43, 11], "Reference"], [[466.0, 119.0, 39, 9], "Reference"], [[457.0, 131.0, 12, 11], "[6]"], [[457.0, 151.0, 23, 15], "[6] [6]"], [[457.0, 173.0, 23, 15], "[6] [6]"], [[442.0, 195.0, 51, 15], "This study[6]"], [[465.0, 217.0, 36, 9], "This study"], [[457.0, 223.0, 12, 11], "[6]"], [[481.0, 239.0, 9, 9], "[6]"], [[457.0, 246.0, 12, 11], "[6]"], [[481.0, 261.0, 9, 9], "[6]"], [[442.0, 281.0, 42, 11], "This study"], [[465.0, 298.0, 36, 9], "This study"], [[442.0, 304.0, 42, 11], "This study"], [[465.0, 320.0, 36, 9], "This study"], [[397.0, 333.0, 132, 11], "First Choice RLM\u2013RACE (RNA"], [[411.0, 345.0, 210, 11], "ligaFsier-smt CedhioaitceedRrLapMid\u2013RaAmC- E (RNA"], [[410.0, 356.0, 174, 11], "pli\ufb01catiolingaosfec-mDNedAiaetenddsr)a,pid"], [[427.0, 368.0, 166, 11], "Tamheprmli\ufb01ocaStcioiennotifficcDNA ends),"], [[409.0, 379.0, 165, 15], "First ChoicTehRerLmMo\u2013SRciAenCtEi\ufb01,c"], [[427.0, 391.0, 156, 15], "ThFeirrmstoCShcoiiecnetRifLicM\u2013RACE,"], [[409.0, 402.0, 165, 15], "First ChoicTehRerLmMo\u2013SRciAenCtEi\ufb01,c"], [[427.0, 413.0, 156, 15], "ThFeirrmstoCShcoiiecnetRifLicM\u2013RACE,"], [[442.0, 424.0, 102, 15], "ThTishesrtumdoy Scienti\ufb01c"], [[442.0, 435.0, 76, 15], "This sTtuhdisystudy"], [[465.0, 446.0, 36, 9], "This study"], [[167.0, 670.0, 342, 9], "Figure 1. Detection of antisense yycF RNA. (A) Total RNA samples were isolated from S. aureus"], [[167.0, 683.0, 328, 9], "to detect ASyycF RNA transcription by \ufb01rst cDNA strand synthesis and RT-PCR (red arrows)."], [[140.0, 696.0, 652, 18], "Figure(1B.)DDeetetectcitoionnofoaf nthtiese5nsteeyrmyciFnRusNoAf. tAh.eTAoStaylyRcFNtArasnasmcrpipletsiownebreyi5solRatAedCEfro(rmedS.aarurorewuss)t:o(a) gene-"], [[140.0, 709.0, 677, 18], "detect AspSeycyi\ufb01cFc RouNteAr tprrainmsecr;ip(bti)ognebnye-fsiprsetcic\ufb01DcNinAnesrtrparnimd esyr;n(tch)easnisda(ndd) aRreT-5PCRRAC(rEedouarteror wansd). iBn.ner primers,"], [[140.0, 722.0, 684, 13], "Detectiroenspoefctthivee5ly\u2032 .te(Crm) iSncuhsemofatthiceoAf SAySyycyFctFrasnhsocwriipntgiotnhabtytr5a\u2032nRsAcrCipEti(ornedstaarrrtoswwsi)t:h(ian)tgheen5e-stepremciifnicus in the"], [[140.0, 733.0, 642, 13], "outer pyryimcFeor;p(ebn) greeandei-nspgefcriafmicein(OneRrFp)r. iTmheerf;u(cll) laenndgt(hd)foarreA5S\u2032yRyAcFCRENoAutiesraapnpdroinxnimerapterliym4e0r0s,brpe.-"], [[140.0, 745.0, 384, 13], "spectively. C. Schematic of ASyycF showing that transcription starts within the 5\u2032 terminus in the"], [[140.0, 756.0, 356, 13], "yycF open reading frame (ORF). The full length for ASyycF RNA is approximately 400 bp."]], [841, 595]], [4, [[[-7.0, 33.0, 92, 15], "OR PEER REVIEW"], [[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[536.0, 54.0, 21, 8], "4 of 12"], [[57.0, 448.0, 870, 19], "FigFuireg2u. rAeSy2y.cFAmSoyduylcaFtedmthoe dbauctlearitael gdrotwhteh abnadcbtioe\ufb01rlimalorggarnoizwattiohn.a(nA)dThbeigorfoiwlmth courrvgesafnorizthaetSiotapnh.ylAoco.c-The growt"], [[57.0, 461.0, 416, 9], "cus aureus. (B) Biomass was quanti\ufb01ed by crystal violet staining. Optical densities at 600 nm were measured (n = 10,"], [[56.0, 470.0, 893, 18], "* pf<o0r.05t)h. e(CS) StEaMphimyalogecsoocfcSu. sauareuusreAuTCs.CB29.21B3,ioanmd masetshiwcillains-rqesuistaannttSitfaipehdylobcoyccucsrayursetuas (lMvRiSoAl)esttrsaitnasianftienr g. Optical"], [[56.0, 487.0, 588, 19], "ASayytcF6o0v0ernexmpreswsioenr. e measured (n = 10, * p < 0.05). C. SEM images of S. aureus ATCC29213, and"], [[67.0, 505.0, 637, 18], "lin-resistant Staph2.y2.loEcffoecctcouf sBiao\ufb01ulmreFuosrm(MatioRnSonAA)nstitbrioatiicnSsenasfittievirtyASyycF overexpression."], [[188.0, 525.0, 335, 10], "The ASyycF-overexpressing MRSA and ATCC29213 strains also showed lower \ufb02uo-"], [[67.0, 537.0, 669, 20], "2.2. Effect of BiofrielsmcenFceoirnmtenasittiyotnhaonntheAMnRtSiAbiaontdicATSCeCn2s9i2t1i3vsittrayins, at half of their parental strains"], [[166.0, 550.0, 348, 10], "(Figure 3A,B). Vancomycin is the primary option for methicillin-resistant Staphylococcus"], [[99.0, 562.0, 821, 21], "The ASyycaFur-eousv(eMrReSxAp) inrfeesctsioinnsg. ByME-RtesSt,AtheasnendsitiAvitTy Cof CMR2S9A2t1o3vasnctormayincinsdaeclrseoasesdhfroowm ed lo"], [[167.0, 575.0, 352, 10], "3 to 1 mg/L after ASyycF overexpression (Figure 3C). ASyycF downregulated the YycFG"], [[67.0, 583.0, 840, 20], "rescence intenspitaythwthayaanndtahsseocMiateRdSviAruleanncedgeAneTexCprCes2si9on2.1R3T-PsCtRrashinowse,datthaht tahlefexopfretshsioenirlevp- arent"], [[67.0, 600.0, 863, 21], "(Figure 3A,B). Velsaonf iccaoAm, icayDc, isanrAi,syyctFh, eandpyryicmG waerreysiognpi\ufb01tciaonntly fdoecrreamsedetinhAicSyiyllcFin-o-vreeresxpisretsasinngt Staph"], [[167.0, 613.0, 359, 10], "MRSA and ATCC29213 strains compared with the parental MRSA and ATCC29213 strains"], [[67.0, 622.0, 810, 20], "aureus (MRSA)(Fiingufreec4tAi)o. Wness.terBnybloEtti-ntgepsrto,bitnhgewitsheanntsi-iYtyivcFiatnytiboofdyMshoRwSedAthattothve parnodcuoctmionycin d"], [[67.0, 638.0, 816, 21], "from 3 to 1 mgo/fLYycaFfpterorteiAn wSaysysicgFni\ufb01ocavnetlyreloxwpesrteinssAiSoyyncF(AFTiCgCu29r2e133ceClls).amAonSgyayllctFhe dgroouwpsnregu"], [[166.0, 650.0, 57, 10], "(Figure 4B,C)."], [[67.0, 660.0, 526, 20], "YycFG pathway and associated virulence gene expression. RT-PCR showed tha"], [[67.0, 680.0, 534, 20], "pression levels of icaA, icaD, sarA, yycF, and yycG were significantly decreased in"], [[67.0, 699.0, 515, 20], "overexpressing MRSA and ATCC29213 strains compared with the parental M"], [[67.0, 718.0, 484, 20], "ATCC29213 strains (Figure 4A). Western blotting probing with anti-YycF"], [[67.0, 737.0, 470, 20], "showed that the production of YycF protein was significantly lowest in"], [[67.0, 757.0, 353, 20], "ATCC29213 cells among all the groups (Figure 4B,C)."]], [841, 595]], [5, [[[35.0, 54.0, 139, 9], "Antibiotics 2021, 10, x60F3OR PEER REVIEW"], [[535.0, 54.0, 38, 9], "55 ooff 1122"], [[57.0, 637.0, 426, 9], "Figure 3. Effect of bio\ufb01lm formation on antibiotics sensitivity. (A) Intensity of \ufb02uorescence for S. aureus ATCC29213, and"], [[57.0, 644.0, 773, 16], "MRSA strains after ASyycF oFviegruerxep3re. sEsfifoenct(socfableiobfailrm= f1o0r0m\u00b5amti)o.n(Bo)nInatnetnibsiitoytiocfs \ufb02seunosrietsivceitnyc.eAc.oImntpeanrsisitoynosfafnlduothreesicnetnecnesiftoiersS."], [[165.0, 654.0, 389, 13], "aureus ATCC29213, and MRSA strains after ASyycF overexpression (scale bar = 100 \u03bcm). B. Inten-"], [[57.0, 662.0, 763, 18], "of S. aureus ATCC29213 weresimtyeoafsuflrueodraesscreenfecreecnocme (pna=ri1so0n, *span<d0.t0h5e).in(Cte)nEs-itteiesst foofrSt.haeusreenussitAivTiCtyCo2f9M21R3SwAetroevmaneacosumryecdina.s"], [[165.0, 679.0, 319, 13], "reference (n = 10, * p < 0.05). C. E-test for the sensitivity of MRSA to vancomycin."]], [841, 595]], [6, [[[-4.0, 35.0, 118, 15], "0, x FOR PEER REVIEW"], [[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[536.0, 54.0, 21, 8], "6 of 12"], [[57.0, 531.0, 420, 9], "Figure 4. ASyycF overexpression inhibited the transcription of bio\ufb01lm-related genes. (A) Quantitative RT-PCR analysis"], [[57.0, 544.0, 858, 19], "showed theFgiegnue trrean4sc.riAptiSonyiyncSF. auorveues,ruesxinpg r16eSsassiaonninitenrnhailbcointterodl (tnh=e10t,r*apn<s0c.0r5i)p; (Bti)oTnheoprfodbuicotifoinlsmof-YryeclFated genes"], [[56.0, 557.0, 430, 9], "were quanti\ufb01ed in the cells of S. aureus for Western blotting (upper lane); the lower panel shows a Coomassie-stained gel"], [[57.0, 566.0, 832, 18], "supportingtievquealRloTad-PinCg oRf eaacnhaplryotseiinsssamhpolwe. (eCd) QtuhaentigtaetinveeantarlaynsissfcorritphetireolantivienYSyc.Fapurorteeuinsa,muosuinntsg(n1=64S, as an int"], [[56.0, 582.0, 520, 19], "* p < 0.05).= 10, * p < 0.05); B. The productions of YycF were quantified in the cells of S. aureus f"], [[98.0, 602.0, 715, 18], "blotting (up2p.3e. rASlayynceF)I;nhthibietedloMwReSAr pInavanseiolnsinhaoRwatsTaibiCal oInofemctioansMsioed-esl tained gel supporting eq"], [[98.0, 619.0, 770, 20], "each protein samMRpSlAe-.inCfe.ctQedutaibniatsitaamtpivlees aat nfoaulrywseieskfsowrertehceolrleecltaedtifvorehYistyocloFgipcarloevtealiunataiomn, ounts"], [[98.0, 637.0, 30, 18], "0.05)."], [[167.0, 633.0, 364, 10], "and contralateral uninfected samples were collected as the control group. In the HE-stained"], [[167.0, 646.0, 357, 10], "samples (Figure 5A, upper lane), substantial destruction in the bone matrix combined with"], [[167.0, 658.0, 344, 10], "a large amount of in\ufb02ammatory in\ufb01ltration was observed in the MRSA group. However,"], [[98.0, 671.0, 714, 20], "2.3. ASyycFin IthnehAibSyityecFdMMRSRASgArouIpn,vthaesiinofnectiinvealeRsioants Thaidbiaalml IonstfreecctoivoenredM, woidthelsigns of"], [[167.0, 683.0, 332, 10], "bone repair (dashed line area). Using a \ufb02uorescently labeled peptide nucleic acid in"], [[130.0, 696.0, 763, 20], "MRSAsi-tuinhfyebrcidteizdatitoinbpiraobseafmor pS.laeusreuast1f6oSurRrNwA,etehekSs. waureeursestcraoinllsewcetreedidefnotri\ufb01hedisatsologic"], [[167.0, 708.0, 339, 10], "\ufb02uorescently labeled green. The \ufb02uorescence intensity of the MRSA group was much"], [[98.0, 715.0, 719, 20], "and contrahligahteerrthaaln uthnationf ftheecAteSydycFsMamRSAplgerosupw(Feigruere c5Ao,lbleotctotmedlanae)s. the control group"], [[98.0, 735.0, 494, 20], "stained samples (Figure 5A, upper lane), substantial destruction in the bon"], [[98.0, 754.0, 499, 20], "bined with a large amount of inflammatory infiltration was observed in the"], [[98.0, 773.0, 484, 20], "However, in the ASyycF MRSA group, the infective lesions had almost re"], [[98.0, 792.0, 500, 20], "signs of bone repair (dashed line area). Using a fluorescently labeled peptid"], [[98.0, 811.0, 498, 20], "in situ hybridization probe for S. aureus 16S rRNA, the S. aureus strains wer"]], [841, 595]], [7, [[[35.0, 54.0, 197, 15], "AAnnttibibioiotticicss22002211, ,1100, ,6x03FOR PEER REVIEW"], [[536.0, 54.0, 38, 15], "77 ooff 1122"], [[57.0, 692.0, 751, 18], "Figure 5. ASyycF inhibited MFRigSuArein5v. aAsSioynyciFnirnahtitbibitieadl iMnfRecStAiveinmvaosdioeln. i(nA)raHt Etibsitaalinininfegcftoivrehmistoodloelg.iAca.lHevEaslutaaitnioinng(fuoprpheirsto-"], [[57.0, 705.0, 769, 18], "lane); the \ufb02uorescent labeled lpoegpictiadleenvualculeaitcioanci(duipnpseitrulahnyeb)r;itdhiezaftliuoonrepsrcoebnint glafboerleSd. apuereputsid(leonwuecrlelaicnea)c.id(Bi)nWsiotrukhinygbmridoidzealt.ion"], [[168.0, 719.0, 212, 13], "probing for S. aureus (lower lane). B. Working model."], [[167.0, 728.0, 58, 10], "3. Discussion"], [[168.0, 743.0, 387, 13], "3. DiSs.cuausrseiuosnis one of the major pathogens of hospital- and community-acquired infec-"], [[167.0, 756.0, 657, 19], "tions,Sr.easuurletuinsgisinonaecroifsitshfeomr haujomr apnathheoaglethn.sAofdhdoitsiopnitaalll-ya, ncodnctoinmumeduannittyib-aiocqtiucierexdpoinsuferce-"], [[167.0, 769.0, 694, 19], "htiaosnesn, arebsleudltiint gtoinacaqucririseisrefsoirsthanucmeatno mheoaslttha.nAtibdidoittiicosn, awlliyth, ctohnetriensuueldt tahnattibthioetpicoepxuplaotsiuorne"]], [841, 595]], [8, [[[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[536.0, 54.0, 21, 8], "8 of 12"], [[167.0, 98.0, 365, 10], "of MRSA accounts for at least 25 to 50% of S. aureus infections in hospitals [17]. Compared"], [[166.0, 111.0, 359, 10], "with methicillin-susceptible strains, MRSA infections have higher mortality rates and health"], [[167.0, 123.0, 361, 10], "care costs [18]. Bio\ufb01lm formation is an essential mechanism for the resistance of S. aureus"], [[167.0, 136.0, 359, 10], "to antibiotics and innate host defense. Hence, many investigations have focused on devel-"], [[167.0, 148.0, 363, 10], "oping novel therapeutic strategies, such as oligonucleotide-based antibacterial strategies to"], [[167.0, 161.0, 366, 10], "tackle bio\ufb01lm-associated infections [5,19,20]. In our current study, an endogenous antisense"], [[167.0, 173.0, 292, 10], "RNA was identi\ufb01ed that could be base-paired with yycF mRNA (Figure 1)."], [[188.0, 186.0, 322, 10], "Once antisense RNA binds to its base-paired mRNA, the expression of the target"], [[167.0, 199.0, 340, 10], "mRNA and the associated downstream translation process can be modulated [15,16]."], [[167.0, 211.0, 341, 10], "For the YycFG TCS, the in\ufb02uence could cause multiple alterations in essential cellular"], [[167.0, 224.0, 354, 10], "metabolism. In our results, the growth rates, bio\ufb01lm formation, and bacterial viability were"], [[167.0, 236.0, 347, 10], "signi\ufb01cantly inhibited by overexpressing antisense yycF in the ASyycF ATCC29213 and"], [[166.0, 249.0, 359, 10], "ASyycF MRSA strains (Figures 2 and 3A,B). Bio\ufb01lms are constructed with microorganisms"], [[167.0, 261.0, 340, 10], "embedded in a self-produced extracellular matrix [21]. As shown in the SEM observa-"], [[167.0, 274.0, 345, 10], "tions, bio\ufb01lm accumulation was obviously decreased in antisense yycF-overexpressing"], [[167.0, 286.0, 352, 10], "strains, which indicated that antisense yycF could negatively regulate bio\ufb01lm metabolism"], [[166.0, 299.0, 346, 10], "(Figure 2C). Indeed, bio\ufb01lms are usually supposed to decrease the sensitivity of bio\ufb01lm"], [[167.0, 312.0, 353, 10], "cells to various antimicrobial agents up to 1000-fold when compared with their planktonic"], [[167.0, 324.0, 354, 10], "forms [10,21,22]. Vancomycin, as the \u201cgold standard\u201d of treatment, has been applied clin-"], [[167.0, 337.0, 339, 10], "ically for serious MRSA infections [23]. In this study, we implemented the vancomycin"], [[167.0, 349.0, 352, 10], "E-test, which indicated that the sensitivity of MRSA was increased with the destruction of"], [[167.0, 362.0, 81, 10], "bio\ufb01lms (Figure 3C)."], [[188.0, 374.0, 323, 10], "YycFG is the only essential TCS that regulates the ica operon, which synthesizes"], [[166.0, 387.0, 342, 10], "polysaccharide intercellular adhesin (PIA) and ica-dependent bio\ufb01lms [10]. Our results"], [[167.0, 399.0, 333, 10], "showed that overexpression of ASyycF RNA inhibited the transcription/translation of"], [[167.0, 412.0, 351, 10], "yycF- and ica-associated genes in ASyycF strains, suggesting that ASyycF could restrict"], [[167.0, 424.0, 340, 10], "ica-dependent bio\ufb01lms via YycFG (Figure 4). Additionally, the expression of the global"], [[167.0, 437.0, 340, 10], "transcriptional regulator staphylococcal accessory regulator operon (sarA) in ASyycF-"], [[167.0, 450.0, 361, 10], "overexpressing strains was reduced (Figure 4). The SarA protein is not only involved in the"], [[167.0, 462.0, 348, 10], "modulation of different virulence-related genes but also impacts ica-independent bio\ufb01lm"], [[166.0, 475.0, 354, 10], "production in S. aureus, which is more frequently isolated from MRSA infections [24]. It is"], [[166.0, 487.0, 353, 10], "proposed that ASyycF has a combined effect in suppressing S. aureus bio\ufb01lm production"], [[167.0, 500.0, 350, 10], "and infections. However, further investigations on how ASyycF inhibited ica and sarA via"], [[166.0, 512.0, 118, 10], "YycFG should be considered."], [[188.0, 525.0, 331, 10], "As a major pathogen for most chronic and recurrent microbial infections in humans,"], [[166.0, 537.0, 347, 10], "S. aureus bio\ufb01lms are involved in a wide range of infections. Some S. aureus infections"], [[167.0, 550.0, 346, 10], "are caused by multidrug-resistant bacteria and even cause high mortality and morbidity"], [[167.0, 563.0, 363, 10], "rates [21,25]. In addition to antibiotic resistance, bio\ufb01lms can evade host immune clearance"], [[167.0, 575.0, 361, 10], "mechanisms and adhere to medical devices such as orthopedic prostheses [24,26]. There-"], [[167.0, 588.0, 348, 10], "fore, eradication of bio\ufb01lms will bene\ufb01t hosts in controlling infection and tissue recovery."], [[166.0, 600.0, 339, 10], "Accordingly, our histology evaluations demonstrated that by intervention with ASyycF,"], [[167.0, 613.0, 347, 10], "the MRSA-infected sites in the rat tibia model tended to recover and featured new bone"], [[167.0, 625.0, 348, 10], "\ufb01lling with few colonies (Figure 5A). Based on these \ufb01ndings, ASyycF has potential as a"], [[167.0, 638.0, 237, 10], "novel antibacterial agent for infection treatment (Figure 5B)."], [[167.0, 660.0, 107, 10], "4. Materials and Methods"], [[167.0, 674.0, 129, 10], "4.1. Bacterial Growth Conditions"], [[188.0, 689.0, 326, 10], "The clinically isolated MRSA strain and the methicillin-sensitive ATCC29213 strain"], [[166.0, 702.0, 363, 10], "provided by the Department of Laboratory Medicine, West China Hospital, were applied [6]."], [[166.0, 714.0, 340, 10], "According to our previous protocol, S. aureus strains were cultured in TSB medium to"], [[167.0, 727.0, 339, 16], "midexponential phase (OD600 = 0.5). For bio\ufb01lm formation, \ufb01ve hundred microliters of"], [[166.0, 739.0, 369, 16], "S. aureus suspension (OD600 = 0.5) were dropped in 24-well polystyrene culture plates (Nest"], [[167.0, 752.0, 356, 10], "Biotechnology, Wuxi, Jiangsu, China) and cultured with 14-mm-diameter glass cover slips"], [[166.0, 765.0, 302, 10], "(Nest Biotechnology, Wuxi, Jiangsu, China) for 24 h for bio\ufb01lm formation [1]."]], [841, 595]], [9, [[[35.0, 54.0, 77, 8], "Antibiotics 2021, 10, 603"], [[536.0, 54.0, 21, 8], "9 of 12"], [[167.0, 98.0, 310, 10], "4.2. 5 -Rapid Ampli\ufb01cation of cDNA Ends (5 -RACE) Assay for Antisense yycF"], [[188.0, 114.0, 341, 10], "Total RNA from midexponential phase ATCC29213 S. aureus strains was puri\ufb01ed with"], [[167.0, 126.0, 351, 10], "a MasterPure RNA Puri\ufb01cation Kit (Epicentre; Illumina Inc, Madison, WI, USA). Samples"], [[167.0, 139.0, 339, 10], "of total RNA were used as templates for the First Strand cDNA Synthesis Kit (Thermo"], [[167.0, 151.0, 363, 10], "Fisher Scienti\ufb01c, Inc., Shanghai, China). According to our previous study [15], the extracted"], [[167.0, 164.0, 351, 10], "RNA samples (20 \u00b5g) were ligated with the 5 -RACE outer adapter using the FirstChoice"], [[167.0, 176.0, 349, 10], "RLM-RACE Kit (Ambion; Thermo Fisher Scienti\ufb01c, Inc., Shanghai, China). Then, nested"], [[167.0, 189.0, 347, 10], "PCR was performed for cDNA ampli\ufb01cation following previous thermocycling conditions"], [[167.0, 202.0, 366, 10], "and sequencing by Sangon Biotech Co., Ltd., Shanghai, China) [15,16]. The oligonucleotide"], [[166.0, 214.0, 360, 10], "primers (SAPCR) for \ufb01rst-strand synthesis PCR and sense strand primers (SAAS) for PCR"], [[167.0, 227.0, 335, 10], "ampli\ufb01cation are listed in Table 1. The 5 -RACE gene-speci\ufb01c outer primer and inner"], [[166.0, 239.0, 271, 10], "primers for the 5 -RLM-RACE PCR assays are also listed in Table 1."], [[167.0, 262.0, 131, 10], "4.3. ASyycF Mutant Construction"], [[188.0, 277.0, 353, 10], "According to the sequencing results noted above, an antisense yycF (ASyycF) sequence"], [[166.0, 290.0, 365, 10], "was designed and expressed by the shuttle plasmid pDL278. According to a previous study,"], [[166.0, 302.0, 346, 10], "ASyycF-overexpressing MRSA and ATCC29213 mutants were constructed [27]. Brie\ufb02y,"], [[166.0, 315.0, 362, 10], "ASyycF sequences were ligated into the pDL278 vector at the BamHI and EcoRI restriction"], [[167.0, 327.0, 347, 10], "sites to synthesize the recombinant plasmid pDL278 ASyycF. Then, the overexpressing"], [[167.0, 340.0, 338, 10], "strains were acquired by transferring the recombinant pDL278 ASyycF plasmid into a"], [[167.0, 353.0, 360, 10], "midexponential phase bacterial suspension with competence-stimulating peptide (CSP) for"], [[167.0, 365.0, 355, 10], "a 60 min incubation. TSB plates containing 1000 \u00b5g/mL spectinomycin and RT-PCR were"], [[167.0, 378.0, 88, 10], "used for identi\ufb01cation."], [[167.0, 400.0, 233, 10], "4.4. Detection of Bacterial Growth and Bio\ufb01lm Assessment"], [[188.0, 415.0, 342, 10], "ATCC29213, ASyycF ATCC29213, MRSA, and ASyycF MRSA strains were cultured in"], [[166.0, 426.0, 356, 16], "TSB at 37 \u25e6C as previously described [28]. Growth curves were measured at OD600 every"], [[167.0, 441.0, 359, 10], "hour. A crystal violet assay was performed to assess the volume of 24 h bio\ufb01lms according"], [[167.0, 453.0, 349, 10], "to our previous study [28]. For the epi\ufb02uorescence test, these bio\ufb01lms were labeled with"], [[167.0, 466.0, 350, 10], "SYTO9 (Invitrogen; Thermo Fisher Scienti\ufb01c, Inc., Shanghai, China). The morphology of"], [[167.0, 478.0, 366, 10], "bio\ufb01lms was detected by scanning electron microscopy (SEM; Inspect, Hillsboro, OR, USA),"], [[167.0, 491.0, 296, 10], "and the samples were prepared as described in our previous protocol [28]."], [[167.0, 513.0, 126, 10], "4.5. Identi\ufb01cation of MIC Values"], [[188.0, 529.0, 314, 10], "TSA plates were used for determining the MICs. Two hundred microliters of the"], [[167.0, 541.0, 367, 10], "suspensions involving ATCC29213, ASyycF ATCC29213, MRSA, and ASyycF MRSA groups"], [[166.0, 554.0, 358, 10], "was spread onto TSA plates. Then, the E-test strips were placed and incubated for 24 h at"], [[167.0, 564.0, 343, 15], "37 \u25e6C. The MIC was identi\ufb01ed as the value at which the inhibition zone intersected the"], [[167.0, 579.0, 97, 10], "scale on the E-strip [29]."], [[167.0, 601.0, 210, 10], "4.6. cDNA Reverse Transcription for RT-PCR Assays"], [[188.0, 615.0, 326, 14], "Total RNA was extracted and puri\ufb01ed using the MasterPureTM RNA Puri\ufb01cation Kit"], [[166.0, 630.0, 349, 10], "(Epicentre Technologies, Epicentre, Madison, WI, USA) according to the manufacturer\u2019s"], [[167.0, 642.0, 335, 10], "instructions. A NanoDrop 2000 spectrophotometer (Thermo Scienti\ufb01c, Waltham, MA,"], [[167.0, 655.0, 354, 10], "USA) was used to detect the purity and concentration of RNAs. Then, the RevertAid First"], [[167.0, 667.0, 350, 10], "Strand cDNA Synthesis Kit (Thermo Scienti\ufb01c) was applied to reverse transcribe RNA to"], [[167.0, 680.0, 342, 10], "cDNA with a random hexamer. The primers used for quantitative real-time polymerase"], [[167.0, 692.0, 356, 10], "chain reaction (qRT-PCR) assays are listed in Table 1. The 16S rRNA gene was set as an"], [[167.0, 702.0, 358, 14], "internal control. Expression differences were calculated according to the 2-\u2206\u2206CT method as"], [[166.0, 717.0, 102, 10], "previously described [10]."], [[167.0, 740.0, 174, 10], "4.7. Protein Extraction and Western Blotting"], [[188.0, 755.0, 336, 10], "S. aureus planktonic samples were collected and disrupted mechanically by a FAST-"], [[167.0, 768.0, 348, 10], "PREP Beater apparatus (MP Biomedicals, Irvine, CA, USA) with glass beads 0.1 mm in"]], [841, 595]]]